In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma's High Hopes for Diabetes Drugs Revived

Executive Summary

If the FDA's decision in September 2005 to ask for additional safety data on the dual PPAR agonist muraglitazar (Pargluva, from Bristol-Myers Squibb and Merck) virtually killed development of all such compounds, the data presented less than a year later at the American Diabetes Association annual meeting has Big Pharma excited again about the potential for new classes of diabetes drugs.
Advertisement

Related Content

Januvia: Defining Primary-Care Success and Risk
Clinical Update (02/2007)
BMS Deals Diabetes Drugs, Solidifies Specialist Stance
BMS Deals Diabetes Drugs, Solidifies Specialist Stance
Satiety: Treating Obesity Beyond Quality of Life
Satiety: Treating Obesity Beyond Quality of Life
Advances in Diabetes Management
VeraLight's Perfect Storm in Diabetes Screening
Devices for a Diabetes Epidemic
VeraLight's Perfect Storm in Diabetes Screening

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002820

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel